Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › AKUMS

AKUMS

Akums Drugs and Pharmaceuticals Limited
Micro-capPharma ↗

What the six lenses say about AKUMS — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹754.6
2026-09-08
VWAP · 1Y anchor
₹553
+36.3% from VWAP
P/E · TTM
46.6×
TTM EPS ₹16.2
52-week range
93%
position low→high
RSI(14)
55
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How AKUMS’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
4.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD788›

The actual numbers

Price vs VWAP (1y)+36.3%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+27.5%
Price vs 50-EMA+7.1%
RSI(14)55
RS vs Nifty 500 · 3M+33.9%
RS vs sector · 3M+27.9%
52-week range93%
Volume vs 30d avg0.51×
Volume vs 60d avg0.48×
ATR(14) · volatility29.9
Bollinger width · vol contraction0.072
FundamentalD330›

The actual numbers

Return on equity (ROE)7.8%
Operating margin10.9%
Net margin5.9%
Revenue growth · YoY+5.9%
EPS growth · YoY-27.0%
Debt / equity0.05×

Full 8-quarter history in the financials table below.

ValuationD310›

The actual numbers

P/E (TTM)46.6×
TTM EPS₹16.2
52-week range93%
CatalystD433›

The actual numbers

Earnings & momentum29
Capital actions6
Governance134

Every filing in the corporate-announcements panel below.

FlowD242›

The actual numbers

Promoter holding75.3%
Delivery · 30d avg53.3%
Up/down-day asymmetry-5.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D7 + D2 ) ÷ 2 = 4.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
83
Conviction score 83/100 · avg-decile strength 4.5/10
Conviction score83/100›
TechnicalD7›
FundamentalD3›
ValuationD3›
CatalystD4›
FlowD2›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-1.0pp
-1.6pp
+17.4pp
+35.5pp
+61.8pp
+65.9pp
Nifty 500
Broad-market baseline
-1.0pp
-1.6pp
+16.3pp
+33.9pp
+56.1pp
+60.7pp
Sector
Own-sector index
—
—
+13.5pp
+27.9pp
+43.0pp
+39.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

AKUMS daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
754.65-11.10

Relative strength

RS vs baseline · rebased to 100

AKUMS ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
88.28-0.92

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,0191,0331,0101,0561,0241,0181,1601,158
↳ change QoQ—+1.4%-2.2%+4.5%-3.0%-0.6%+13.9%-0.2%
EBITDA (₹cr)1351381419412994147152
EBITDA margin13.2%13.4%13.9%8.9%12.6%9.2%12.7%13.1%
PAT (₹cr)61676615065436881
↳ change QoQ—+8.9%-0.5%+126.2%-56.7%-33.8%+58.1%+19.1%
Net margin6.0%6.5%6.6%14.2%6.3%4.2%5.9%7.0%
EPS (₹)4.214.374.269.384.032.594.215.38
D/E————————
YoY growth · Mar '26Revenue +9.7% YoYPAT -46.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 3 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Monitoring Agency Report
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 8 Aug '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Jul '26
    LOWgovernance
    Action(s) taken or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds AKUMS

Mutual funds holding AKUMS (7)

FundWeightAUM ₹crGrade
Franklin India Small Cap Gr0.96%14,467
Nippon India Pharma Gr1.00%9,279
Nippon India Pharma Bns1.00%9,279
ICICI Pru Pharma Healthcare Diag Gr1.89%6,803
Franklin India Multi Cap Reg Gr1.35%5,096
Old Bridge Flexi Cap Reg Gr2.39%256
Samco Multi Cap Reg Gr0.60%228

ETFs holding AKUMS (0)

No tracked ETF holds AKUMS ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma